Truist initiated coverage on BeOne Medicines
$ONC
Biotechnology: Pharmaceutical Preparations
Health Care
Truist initiated coverage of BeOne Medicines with a rating of Buy
Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 11/24/2025 | Buy | Truist | |
| 9/18/2025 | $385.00 | Overweight | Barclays |
| 4/7/2025 | $312.00 | Outperform | RBC Capital Mkts |
| 3/3/2025 | $207.00 → $320.00 | Neutral → Buy | BofA Securities |
If approved, sonrotoclax will become the first BCL2 inhibitor for R/R MCL in the U.S., addressing a high unmet need in an aggressive cancer Sonrotoclax previously received Breakthrough Therapy Designation based on clinically meaningful, rapid responses in R/R MCL BeOne Medicines will present the data supporting the NDA and Priority Review for the first time at ASH 2025 BeOne Medicines Ltd. (NASDAQ:ONC, HKEX: 06160, SSE: 688235)), a global oncology company, today announced that the U.S. Food and Drug Administration (FDA) has accepted and granted Priority Review to a New Drug Application (NDA) for sonrotoclax, a next-generation BCL2 inhibitor, for the treatment of adult patients with relap
BRUKINSA now demonstrates best-in-class sustained efficacy and long-term benefit with a favorable safety profile over more than six years of follow-up data in treatment-naïve and R/R CLL First results from Phase 1/2 sonrotoclax monotherapy study will demonstrate notable speed and depth of clinical responses in patients with R/R MCL, a rare, aggressive cancer New efficacy and safety data will highlight the benefits of potential first-in-class BTK degrader BGB-16673 in patients across multiple hematological malignancies BeOne Medicines Ltd. (NASDAQ:ONC, HKEX: 06160, SSE: 688235)), a global oncology company, advances its vision to become the world's leading oncology company with extensiv
ZIIHERA plus TEVIMBRA and chemotherapy demonstrated clinically meaningful and statistically significant improvements in PFS and OS versus trastuzumab and chemotherapy ZIIHERA plus chemotherapy showed a clinically meaningful and statistically significant improvement in PFS versus trastuzumab and chemotherapy, and a clinically meaningful effect with a strong trend toward statistical significance for OS at the first interim analysis First Phase 3 trial in 15 years to demonstrate a clinical benefit in this patient population with a novel HER2-targeted therapy BeOne Medicines Ltd. (NASDAQ:ONC, HKEX: 06160, SSE: 688235)), a global oncology company, today announced positive top-line results
8-K - BeOne Medicines Ltd. (0001651308) (Filer)
10-Q - BeOne Medicines Ltd. (0001651308) (Filer)
8-K - BeOne Medicines Ltd. (0001651308) (Filer)
Truist initiated coverage of BeOne Medicines with a rating of Buy
Barclays initiated coverage of BeOne Medicines with a rating of Overweight and set a new price target of $385.00
RBC Capital Mkts initiated coverage of BeiGene with a rating of Outperform and set a new price target of $312.00
4 - BeOne Medicines Ltd. (0001651308) (Issuer)
4 - BeOne Medicines Ltd. (0001651308) (Issuer)
4 - BeOne Medicines Ltd. (0001651308) (Issuer)
DIAMOND BAR, Calif., Oct. 21, 2025 /PRNewswire/ -- The Institute for Follicular Lymphoma Innovation (IFLI), a global, non-profit, private foundation dedicated to accelerating the development of innovative treatment options for patients with follicular lymphoma (FL)., today announced the appointments of Mehrdad Mobasher, M.D., M.P.H., and Carol O'Hear, M.D., Ph.D., as Executive Partners. "I believe Carol and Mehrdad will be exceptional partners to the IFLI team and portfolio as they bring decades of strategic leadership and drug development expertise," said David McCullagh, Man
Third quarter total revenues increased 41% to $1.4 billion versus third quarter 2024 Global BRUKINSA® (zanubrutinib) revenues increased 51% to $1.0 billion versus third quarter 2024 Diluted GAAP Earnings per American Depository Share (ADS) of $1.09, non-GAAP diluted Earnings per ADS of $2.65 47 abstracts accepted at American Society of Hematology (ASH) Annual Meeting BeOne Medicines Ltd. (NASDAQ:ONC, HKEX: 06160, SSE: 688235)), a global oncology company, today announced financial results and corporate updates from the third quarter of 2025. "These strong financial results reinforce our position as a global oncology leader with exceptional topline growth and a strong balance sheet,
Second quarter total revenues increased 42% to $1.3 billion versus second quarter 2024 Global BRUKINSA revenues increased 49% to $950 million versus second quarter 2024 Reported diluted GAAP Earnings per American Depositary Share (ADS) of $0.84, non-GAAP diluted Earnings per ADS of $2.25 Anticipate 20+ milestones in next 18 months across hematology and solid tumor pipeline BeOne Medicines Ltd. (NASDAQ:ONC, HKEX: 06160, SSE: 688235)), a global oncology company, today announced financial results and corporate updates from the second quarter of 2025. "Our strong second quarter performance reinforces our trajectory as a global oncology powerhouse and underscores our proven abilit
First quarter 2025 total revenues increased 49% to $1.1 billion with BRUKINSA® (zanubrutinib) global sales increasing 62% to $792 million on strong demand growth versus first quarter 2024 Achieved GAAP profitability and significantly improved operating cash flow Advanced late-stage hematology and solid tumor pipelines with plan to host Investor R&D Day on June 26 Secured shareholder approval to rename the Company to BeOne Medicines Ltd. and redomicile to Switzerland BeiGene, Ltd. (NASDAQ:ONC, HKEX: 06160, SSE: 688235)), a global oncology company that will change its name to BeOne Medicines, Ltd., today announced financial results and corporate updates from the first quarter 2025.